vs
Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and Galecto, Inc. (GLTO). Click either name above to swap in a different company.
Galecto, Inc. is the larger business by last-quarter revenue ($1.0M vs $862.0K, roughly 1.2× Coeptis Therapeutics Holdings, Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -20053.5%, a 19907.1% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
COEP vs GLTO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $862.0K | $1.0M |
| Net Profit | $-1.3M | $-200.7M |
| Gross Margin | 94.8% | — |
| Operating Margin | -230.6% | -20149.5% |
| Net Margin | -146.5% | -20053.5% |
| Revenue YoY | — | 339.0% |
| Net Profit YoY | 55.1% | -2877.8% |
| EPS (diluted) | $0.05 | $10.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $862.0K | $1.0M | ||
| Q3 25 | $237.4K | — | ||
| Q2 25 | $200.7K | — | ||
| Q1 25 | $62.9K | — | ||
| Q4 24 | $0 | $228.0K | ||
| Q3 24 | $0 | $146.0K | ||
| Q2 24 | $0 | $213.0K | ||
| Q1 24 | $0 | $257.0K |
| Q4 25 | $-1.3M | $-200.7M | ||
| Q3 25 | $-2.9M | — | ||
| Q2 25 | $-4.3M | — | ||
| Q1 25 | $-3.4M | — | ||
| Q4 24 | $-2.8M | $-6.7M | ||
| Q3 24 | $-1.8M | $-3.9M | ||
| Q2 24 | $-3.0M | $-5.3M | ||
| Q1 24 | $-3.0M | $-5.5M |
| Q4 25 | 94.8% | — | ||
| Q3 25 | 81.0% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 28.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -230.6% | -20149.5% | ||
| Q3 25 | -1043.2% | — | ||
| Q2 25 | -2252.9% | — | ||
| Q1 25 | -6452.6% | — | ||
| Q4 24 | — | -3114.9% | ||
| Q3 24 | — | -2630.1% | ||
| Q2 24 | — | -2618.3% | ||
| Q1 24 | — | -2233.9% |
| Q4 25 | -146.5% | -20053.5% | ||
| Q3 25 | -1220.8% | — | ||
| Q2 25 | -2159.9% | — | ||
| Q1 25 | -5440.9% | — | ||
| Q4 24 | — | -2956.6% | ||
| Q3 24 | — | -2659.6% | ||
| Q2 24 | — | -2506.1% | ||
| Q1 24 | — | -2131.1% |
| Q4 25 | $0.05 | $10.86 | ||
| Q3 25 | $-0.58 | — | ||
| Q2 25 | $-1.17 | — | ||
| Q1 25 | $-1.11 | — | ||
| Q4 24 | $-5.35 | $-5.17 | ||
| Q3 24 | $-0.05 | $-3.39 | ||
| Q2 24 | $-0.08 | $-4.92 | ||
| Q1 24 | $-0.08 | $-5.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $676.6K | $257.6M |
| Total DebtLower is stronger | $150.0K | — |
| Stockholders' EquityBook value | $13.6M | $240.4M |
| Total Assets | $16.2M | $260.5M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $676.6K | $257.6M | ||
| Q3 25 | $421.7K | — | ||
| Q2 25 | $990.6K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $14.2M | ||
| Q3 24 | — | $19.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $27.2M |
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | $13.6M | $240.4M | ||
| Q3 25 | $10.4M | — | ||
| Q2 25 | $6.1M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $3.4M | $15.8M | ||
| Q3 24 | $4.8M | $20.9M | ||
| Q2 24 | $-442.6K | $23.6M | ||
| Q1 24 | $-1.1M | $28.2M |
| Q4 25 | $16.2M | $260.5M | ||
| Q3 25 | $14.2M | — | ||
| Q2 25 | $12.2M | — | ||
| Q1 25 | $13.5M | — | ||
| Q4 24 | $8.9M | $17.1M | ||
| Q3 24 | $9.0M | $23.4M | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $3.9M | $32.5M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $566.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.6M | $566.0K | ||
| Q3 25 | $-2.2M | — | ||
| Q2 25 | $-2.4M | — | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-6.6M | $-4.9M | ||
| Q3 24 | $-1.9M | $-3.7M | ||
| Q2 24 | $-1.4M | $-4.1M | ||
| Q1 24 | $-1.9M | $-5.9M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
